Related Experiment Video
Updated: Mar 12, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in
Daijun Zhao1, Ruoyan Gai Tobe2, Min Cui3
1Hongkou CDC, Shanghai, China.
Background:
To evaluate the cost-effectiveness of adding 23-valent pneumococcal polysaccharide vaccine (PPSV23) to the immunization schedule for the elderly population (age>60years) in Shanghai, China.
Methods:
A decision-tree model, with data and assumptions adapted from the societal perspective of Shanghai City, was developed to project the health outcomes of PPSV23 vaccination (compared with no vaccination) over a lifetime course. Sensitivity analysis was used to test the model's robustness. The clinical data, utility and treatment costs related to pneumococcal diseases were either cited from the literature or calculated from local sources.
Results:
The incremental cost-effectiveness ratio of PPSV23 vaccination compared with no vaccination was $16,699/quality-adjusted life years gained, which was lower than the per capita GDP of Shanghai ($16,840). Sensitivity analyses showed that the model's outcome is robust.
Conclusions:
Routine vaccination of the elderly population with PPSV23 is cost-effective in Shanghai, China.
Related Concept Videos
Drug Dosing: Geriatric Patients
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pneumonia III: Complications and Assessment
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

